Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2)

November 10, 2016

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2)

Lancet – November 2016

Kerr-et-al-Lancet-Oncology-2016-

Share This Post

LinkedInMessengerWhatsApp

More Posts

IngenOx Therapeutics Company Update and Board Reshuffle

May 10, 2024

IngenOx Therapeutics Contributes to Review of Diagnostic Biomarkers for Precision Bowel Cancer Adjuvant Therapy

December 7, 2023

IngenOx Therapeutics Receives Granted Patents from the EU and China for PRMT5 Inhibitor-based Drugs.

October 6, 2023